denufosol
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00210093 | Apr → May 2003 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00210054 | Nov → Dec 2002 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00210067 | May 2001 → Jun 2002 | retinal detachment | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00034515 | Jun 2001 → Aug 2002 | cystic fibrosis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT01181622 | Aug → Oct 2010 | cystic fibrosis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00425165 | Aug 2007 → May 2008 | cystic fibrosis | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00114062 | Sep 2005 → Dec 2006 | cystoid macular edema, uveitis | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00130182 | Aug 2005 → Sep 2006 | cystic fibrosis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00135655 | Aug 2005 → ? | cystoid macular edema | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 2 | NCT00103714 | Jan → Aug 2005 | cystic fibrosis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00083967 | Jun 2004 → Apr 2006 | retinal detachment | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00056147 | Apr 2003 → Feb 2004 | cystic fibrosis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 33 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT00846781 | Feb 2009 → Feb 2011 | cystic fibrosis | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT00625612 | Feb 2008 → Oct 2010 | cystic fibrosis | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 3 | NCT00357279 | Jul 2006 → Sep 2008 | cystic fibrosis | Merck Sharp & Dohme LLC | Completed | Met primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | denufosol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00103714 ↗ |
| Known as | denufosol tetrasodium | “Denufosol tetrasodium (INS37217) is a selective P2Y(2) agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia,...” PMID 15704203 ↗ Apr 200513“The objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of two dose levels of INS37217 (denufosol tetrasodium) Inhalation Solution in...” NCT00103714 ↗ “Drug: Denufosol Tetrasodium (INS37217) Inhalation Solution, Denufosol 60 mg is administered as an inhalation solution, three times daily for twelve months.” NCT00625612 ↗ “denufosol tetrasodium (INS37217) Intravitreal Injection” NCT00114062 ↗ “denufosol tetrasodium (INS37217) Intravitreal Injection” NCT00210067 ↗ “denufosol tetrasodium (INS37217) Intravitreal Injection” NCT00083967 ↗ “denufosol tetrasodium (INS37217) Intravitreal Injection” NCT00135655 ↗ “denufosol tetrasodium (INS37217) Inhalation Solution” NCT00357279 ↗ “denufosol tetrasodium (INS37217) Inhalation Solution” NCT00425165 ↗ “denufosol tetrasodium Inhalation Solution” NCT01181622 ↗ “denufosol tetrasodium (INS37217)” NCT00210093 ↗ |
| Known as | INS37217 | “Denufosol tetrasodium (INS37217) is a selective P2Y(2) agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia,...” PMID 15704203 ↗ Apr 200512“The objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of two dose levels of INS37217 (denufosol tetrasodium) Inhalation Solution in...” NCT00103714 ↗ “Drug: Denufosol Tetrasodium (INS37217) Inhalation Solution, Denufosol 60 mg is administered as an inhalation solution, three times daily for twelve months.” NCT00625612 ↗ “denufosol tetrasodium (INS37217) Intravitreal Injection” NCT00210067 ↗ “denufosol tetrasodium (INS37217) Intravitreal Injection” NCT00114062 ↗ “denufosol tetrasodium (INS37217) Intravitreal Injection” NCT00135655 ↗ “denufosol tetrasodium (INS37217) Intravitreal Injection” NCT00083967 ↗ “denufosol tetrasodium (INS37217) Inhalation Solution” NCT00425165 ↗ “denufosol tetrasodium (INS37217) Inhalation Solution” NCT00357279 ↗ “denufosol tetrasodium (INS37217)” NCT00130182 ↗ “denufosol tetrasodium (INS37217)” NCT00056147 ↗ |
| Action | Activate | “Denufosol tetrasodium is a selective P2Y(2) agonist” PMID 17446337 ↗ Apr 2007 |
| Modality | Other / unclassified | “Denufosol is a novel ion channel regulator” PMID 21169471 ↗ Dec 2010 |
| Route | Other | “administered by inhalation via the Pari LC Star nebulizer” NCT00034515 ↗ |